Lamotrigine and Levetiracetam Serum/Plasma Levels and Toxicity

Supplementary file 1: Data for 5,046 measurements of lamotrigine serum/plasma drug levels on 1,930 unique patients (1,068 female, 862 male). The retrospective timeframe is August 1, 1996 through November 15, 2018. Supplementary file 2: Data for 597 measurements on 293 unique patients (163 female, 130 male) for which the lamotrigine serum/plasma drug level was greater than 14.0 mg/L. Data includes information from detailed chart review. The retrospective timeframe is August 1, 1996 through November 15, 2018. Supplementary file 3: Data for 4,359 measurements of levetiracetam serum/plasma drug levels on 2,451 unique patients (1,225 female, 1,226 male). The retrospective timeframe is January 1, 2005 and November 15, 2018. Supplementary file 4: Data for 134 measurements on 106 unique patients (33 female, 73 male) for which the levetiracetam serum/plasma drug level was 80 mg/L or higher. Data includes information from detailed chart review. The retrospective timeframe is January 1, 2005 and November 15, 2018.